Clinical Biological and Pharmacological Factors Influencing Stroke Outcome (biostroke)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00763217 |
Recruitment Status
:
Completed
First Posted
: September 30, 2008
Last Update Posted
: May 13, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Stroke |
In the cohort, the severity of stroke (NIHSS) will be correlated with :
- clinical factors,
- pharmacological factors,
- biological factors (inflammatory markers, hemostasis...)
Study Type : | Observational |
Actual Enrollment : | 550 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Characterization of Clinical, Biological and Pharmacological Markers of Stroke Outcome |
Study Start Date : | June 2005 |
Actual Primary Completion Date : | June 2009 |
Actual Study Completion Date : | June 2012 |
Group/Cohort |
---|
stroke patient cohort
Patients with an hemispheric ischemic or hemorrhage stroke hospitalized during the 48h following the beginning of stroke
|
- severity of stroke measured by NIH severity score [ Time Frame: inclusion, day7, month3, year3 ]
- clinical, pharmacological and biological (metabolic, inflammation, hemostasis...) cognitive status [ Time Frame: inclusion and year3 ]
Biospecimen Retention: Samples Without DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 40 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- ischemic or hemorrhage stroke
- hemispheric stroke
- stroke dating from less 48h
Exclusion Criteria:
- non hemispheric stroke
- malformative intracranial hemorrhage
- traumatic intracranial hemorrhage
- subarachnoidal hemorrhage

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00763217
France | |
Lille University Hospital - Service de Neurologie vasculaire | |
Lille, France |
Principal Investigator: | regis BORDET, MD,PhD | Lille University Hospital |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | University Hospital, Lille |
ClinicalTrials.gov Identifier: | NCT00763217 History of Changes |
Other Study ID Numbers: |
CP 05/15 PHRC 2004/1901 ( Other Identifier: DHOS ) |
First Posted: | September 30, 2008 Key Record Dates |
Last Update Posted: | May 13, 2015 |
Last Verified: | May 2015 |
Keywords provided by University Hospital, Lille:
inflammation coagulation neuroprotection drugs |
clinical neurology pharmacology biological factors |
Additional relevant MeSH terms:
Stroke Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Vascular Diseases Cardiovascular Diseases |